Janssen-Cilag Pty Ltd v Pfizer Pty Ltd

In the Federal Court of Australia, the case of Janssen-Cilag Pty Ltd v Pfizer Pty Ltd revolved around the question of whether reliance was a necessary condition for a competitor to claim damages under Part V of the Trade Practices Act 1974. Janssen-Cilag, a pharmaceutical company, sought damages from Pfizer Pty Ltd for losses allegedly incurred due to Pfizer’s conduct that contravened the Act. The dispute centred on whether Janssen, despite not relying on Pfizer’s contravening conduct, could still claim damages for the harm suffered as a result of the contravention.

The court was tasked with determining whether the reliance of the injured party on the contravening conduct was a prerequisite for awarding damages, or if the harm itself was sufficient grounds for compensation. Specifically, the court needed to assess whether Janssen, having suffered damages due to Pfizer's actions, could recover damages even if it had not relied on the contravening conduct.

The court ruled that reliance was not a necessary precondition for awarding damages under the Act. The reasoning was that the purpose of Part V of the Act is to prevent and remedy anti-competitive conduct, and the harm caused by such conduct is sufficient to warrant compensation regardless of whether the injured party relied on the contravening conduct. The court found that paragraph 4 of the Defence, which argued that reliance was necessary, was not a valid legal defence. The Court ordered that the question before it be answered in the negative, and that any further discussion on costs and directions would be postponed to a later date.